Low bone mineral density in patients with type 1 diabetes: association with reduced expression of IGF1, IGF1R and TGF B 1 in peripheral blood mononuclear cells

Diabetes/Metabolism Research and Reviews

Volumn 32, Issue 6, 2016, Pages 589-595

  de Souza, Karla Simone Costa ^a   Ururahy, Marcela Abbott Galvão ^a   da Costa Oliveira, Yonara Monique ^a   Loureiro, Melina Bezerra ^a   da Silva, Heglayne Pereira Vital ^a   Bortolin, Raul Hernandes ^a   Melo dos Santos, Fabricio ^a   Luchessi, André Ducati ^a   Neto, José Jorge Maciel ^a   Arrais, Ricardo Fernando ^a   Hirata, Rosario Dominguez Crespo ^b   das Graças Almeida, Maria ^a   Hirata, Mario Hiroyuki ^b   de Rezende, Adriana Augusto ^a  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO NORTE   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

IGF1; IGF1R; low BMD; mRNA expression; TGFB1; type 1 diabetes

Indexed keywords

ALBUMIN; CREATININE; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; TRANSFORMING GROWTH FACTOR BETA1;

ADOLESCENT; ADULT; ALBUMINURIA; ARTICLE; BONE DENSITY; CALCIUM BLOOD LEVEL; CHILD; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; GLYCEMIC CONTROL; HEMOGLOBIN DETERMINATION; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION;

EID: 84985942507     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.2772     Document Type: Article

References (37)

1. Bakker NE, Kuppens RJ, Siemensma EPC, et al. Bone mineral density in children and adolescents with Prader–Willi syndrome: a longitudinal study during puberty and 9 years of growth hormone treatment. J Clin Endocrinol Metab 2015; 100: 1609–1618.
2. Roggen I, Gies I, Vanbesien J, Louis O, De Schepper J. Trabecular bone mineral density and bone geometry of the distal radius at completion of pubertal growth in childhood type 1 diabetes. Horm Res Pædiatrics 2013; 79: 68–74.
3. Hamann C, Kirschner S, Günther K, Hofbauer LC. Bone, sweet bone – osteoporotic fractures in diabetes mellitus. Nat Rev Endocrinol 2012; 8: 297–305.
4. Dhaon P, Shah VN. Type 1 diabetes and osteoporosis: a review of literature. Indian J Endocrinol Metab 2014; 18: 159–165.
5. Vestergaard P. Diabetes and bone. J Diabetes Metab 2012; 01: 1–7.
6. Zhukouskaya VV, Shepelkevich AP, Chiodini I. Bone health in type 1 diabetes: where we are now and how we should proceed. Adv Endocrinol 2014; 2014: 1–12.
7. Locatelli V, Bianchi V. Effect of GH/IGF-1 on bone metabolism and osteoporosis. Int J Endocrinol 2014; 2014. doi:10.1155/2014/235060.
8. Sealand R, Razavi C, Adler RA. Diabetes mellitus and osteoporosis. Curr Diab Rep 2013; 13: 411–418.
9. Moyer-Mileur LJ, Slater H, Jordan KC, Murray MA. IGF-1 and IGF-binding proteins and bone mass, geometry, and strength: relation to metabolic control in adolescent girls with type 1 diabetes. J Bone Miner Res 2008; 23: 1884–1891.
10. AboElAsrar MA, Elbarbary NS, Elshennawy DE, Omar AM. Insulin-like growth factor-1 cytokines cross-talk in type 1 diabetes mellitus: relationship to microvascular complications and bone mineral density. Cytokine 2012; 59: 86–93.
11. Zhao Y-F, Zeng D-L, Xia L-G, et al. Osteogenic potential of bone marrow stromal cells derived from streptozotocin-induced diabetic rats. Int J Mol Med 2013; 31: 614–620.
12. Kaiser G, Thomas A, Köttstorfer J, Kecht M, Sarahrudi K. Is the expression of transforming growth factor-beta1 after fracture of long bones solely influenced by the healing process? Int Orthop 2012; 36: 2173–2179.
13. Klöting N, Follak N, Klöting I. Diabetes per se and metabolic state influence gene expression in tissue-dependent manner of BB/OK rats. Diabetes Metab Res Rev 2005; 21: 281–287.
14. Priyadarshi S, Ray CS, Panda KC, et al. Genetic association and gene expression analysis of TGFB1 contributes towards the susceptibility to otosclerosis. J Bone Miner Res 2013; 28: 2490–2497.
15. Hopwood B, Tsykin A, Findlay DM, Fazzalari NL. Gene expression profile of the bone microenvironment in human fragility fracture bone. Bone 2009; 44: 87–101.
16. Langdahl BL, Uitterlinden AG, Ralston SH, et al. Large-scale analysis of association between polymorphisms in the transforming growth factor beta 1 gene (TGFB1) and osteoporosis: the GENOMOS study. Bone 2008; 42: 969–981.
17. American Diabetes Association. 2. Classification and diagnosis of diabetes. Diabetes Care 2015; 38: S8–S16.
18. American Diabetes Association. 6. Glycemic targets. Diabetes Care 2015; 38: S33–S40.
19. Tanner JM. Principles of growth standards. Acta Paediatr Scand 1990; 79: 963–967.
20. Bachrach LK, Sills IN. Clinical report – bone densitometry in children and adolescents. Pediatrics 2011; 127: 189–194.
21. Sambrook J, Russell D. Molecular Cloning: A Laboratory Manual. Volume 1 (3rd edn). Cold Spring Harbor Laboratory Press: New York, 2001.
22. Vandesompele J, De Preter K, Pattyn F, et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 2002; 3: 1–12.
23. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001; 25: 402–408.
24. Baron R, Kneissel M. WNT signaling in bone homeostasis and disease: from human mutations to treatments. Nat Med 2013; 19: 179–192.
25. Joshi A, Varthakavi P, Chadha M, Bhagwat N. A study of bone mineral density and its determinants in type 1 diabetes mellitus. J Osteoporos 2013; 2013: 1–8.
26. Vargas DM, Rigotti T, Gütz CNRM, Lobe MCS, Fernades JDA. Bone mineralization in children and adolescents with type 1 diabetes. J Pediatr (Rio J) 2003; 79: 253–258.
27. Brandao FR, Vicente EJ, Daltro CH, Sacramento M, Moreira A, Adan L. Bone metabolism is linked to disease duration and metabolic control in type 1 diabetes mellitus. Diabetes Res Clin Pract 2007; 78: 334–339.
28. Loureiro MB, Ururahy MAG, Freire-Neto FP, et al. Low bone mineral density is associated to poor glycemic control and increased OPG expression in children and adolescents with type 1 diabetes. Diabetes Res Clin Pract 2014; 103: 452–457.
29. Jamal SA, Swan VJD, Brown JP, et al. Kidney function and rate of bone loss at the hip and spine: the Canadian Multicentre Osteoporosis Study. Am J Kidney Dis 2010; 55: 291–299.
30. Vestergaard P, Rejnmark L, Mosekilde L. Diabetes and its complications and their relationship with risk of fractures in type 1 and 2 diabetes. Calcif Tissue Int 2009; 84: 45–55.
31. Guntur AR, Rosen CJ. IGF-1 regulation of key signaling pathways in bone. Bonekey Rep 2013; 2: 437.
32. Perrini S, Laviola L, Carreira MC, Cignarelli A, Natalicchio A, Giorgino F. The GH/IGF1 axis and signaling pathways in the muscle and bone: mechanisms underlying age-related skeletal muscle wasting and osteoporosis. J Endocrinol 2010; 205: 201–210.
33. Maor G, Karnieli E. The insulin-sensitive glucose transporter (GLUT4) is involved in early bone growth in control and diabetic mice, but is regulated through the insulin-like growth factor I receptor. Endocrinol 1999; 140: 1841–1851.
34. Kubiczkova L, Sedlarikova L, Hajek R, Sevcikova S. TGF-β – an excellent servant but a bad master. J Transl Med 2012; 10: 183.
35. Siqueira MF, Flowers S, Bhattacharya R, et al. FOXO1 modulates osteoblast differentiation. Bone 2011; 48: 1043–1051.
36. Kasagi S, Chen W. TGF-beta1 on osteoimmunology and the bone component cells. Cell Biosci 2013; 3: 4.
37. Rhodes SD, Wu X, He Y, et al. Hyperactive transforming growth factor-β1 signaling potentiates skeletal defects in a neurofibromatosis type 1 mouse model. J Bone Miner Res 2013; 28: 2476–2489.